Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,915 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Why do cervids feed on aquatic vegetation?
Ceacero F, Landete-Castillejos T, Miranda M, García AJ, Martínez A, Gallego L. Ceacero F, et al. Among authors: miranda m. Behav Processes. 2014 Mar;103:28-34. doi: 10.1016/j.beproc.2013.10.008. Epub 2013 Nov 9. Behav Processes. 2014. PMID: 24220797
Characterization of the Common Genetic Variation in the Spanish Population of Navarre.
Maillo A, Huergo E, Apellániz-Ruiz M, Urrutia-Lafuente E, Miranda M, Salgado J, Pasalodos-Sanchez S, Delgado-Mora L, Teijido Ó, Goicoechea I, Carmona R, Perez-Florido J, Aquino V, Lopez-Lopez D, Peña-Chilet M, Beltran S, Dopazo J, Lasa I, Beloqui JJ, Nagen-Scheme, Alonso Á, Gomez-Cabrero D. Maillo A, et al. Among authors: miranda m. Genes (Basel). 2024 May 4;15(5):585. doi: 10.3390/genes15050585. Genes (Basel). 2024. PMID: 38790214
Trace element status in canine endocrine diseases.
Larrán B, Loste A, Borobia M, Miranda M, López-Alonso M, Herrero-Latorre C, Marca MC, Orjales I. Larrán B, et al. Among authors: miranda m. Res Vet Sci. 2024 May 19;174:105309. doi: 10.1016/j.rvsc.2024.105309. Online ahead of print. Res Vet Sci. 2024. PMID: 38781816
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.
Goodyear CS, Patel A, Barnes E, Willicombe M, Siebert S, de Silva TI, Snowden JA, Lim SH, Bowden SJ, Billingham L, Richter A, Carroll M, Carr EJ, Beale R, Rea D, Parry H, Pirrie S, Lim Z, Satsangi J, Dunachie SJ, Cook G, Miller P, Basu N, Gilmour A, Hodgkins AM, Evans L, Hughes A, Longet S, Meacham G, Yong KL, A'Hearne MJ, Koh MBC, Burns SO, Orchard K, Paterson C, McIlroy G, Murray SM, Thomson T, Dimitriadis S, Goulston L, Miller S, Keillor V, Prendecki M, Thomas D, Kirkham A, McInnes IB, Kearns P; OCTAVE-DUO investigators. Goodyear CS, et al. Lancet Rheumatol. 2024 Jun;6(6):e339-e351. doi: 10.1016/S2665-9913(24)00065-1. Epub 2024 May 8. Lancet Rheumatol. 2024. PMID: 38734019 Free article. Clinical Trial.
2,915 results